CN1582976A - Extraction of styptic from cephalanoplos segetum - Google Patents
Extraction of styptic from cephalanoplos segetum Download PDFInfo
- Publication number
- CN1582976A CN1582976A CN 03134512 CN03134512A CN1582976A CN 1582976 A CN1582976 A CN 1582976A CN 03134512 CN03134512 CN 03134512 CN 03134512 A CN03134512 A CN 03134512A CN 1582976 A CN1582976 A CN 1582976A
- Authority
- CN
- China
- Prior art keywords
- water
- ethyl acetate
- medical material
- extraction
- volume
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
A process for preparing the styptic in the form of injection from cephalanoplos herb includes such steps as decocting, vacuum concentrating, macroreticular adsorbing and freeze drying.
Description
One, technical field
The present invention relates to a kind of method of extracting haemostatic medicament from plant, specifically a kind of method of extracting haemostatic medicament from the Herba Cirsii plant belongs to extract drugs method and technology field.
Two, background technology
Hemorrhage is the important clinical symptom of many surgery and medicine diseases, and the clinical danger of polyphyly, urgency, serious symptom.Can cause shock when going out hyperhematosis, cause life danger, simultaneously, hemorrhage also with pain, inflammation etc.If hemorrhage can not in time the hemostasis then can be deposited in vivo, cause other disease.Therefore, hemostasis is an important means of handling clinical hemorrhagic severe crisis, in addition, considers that from military medical angle hemorrhage is one of important content of the strategic medicine of war preparedness, and therefore, haemostatic medicament has purposes widely.
At present, haemostatic medicament is distinguished from the approach that obtains Chinese medicine, synthetic drug and biological engineering medicine three major types.Synthetic drug and biological engineering medicine mostly are unification compound or enzyme preparation, act on single target spot, or be vasoconstrictor or for the coagulant thing, because its action target spot is single, so the hemorrhage for different reasons and different mechanisms is difficult to obtain extensively and satisfied curative effect, and easily produce toxic and side effects, as blood pressure sharply rising, thrombosis, bring out cardiovascular and cerebrovascular disease etc.The Chinese medicine hemorrhage has many target spots, multicomponent, synergistic characteristics, but each link of vasoactive, blood, especially contain multiple thrombin activator, coagulation process is " chain-type " and reaches " waterfall type " reaction, increased blood coagulation activity, reduce toxic and side effects, strengthened the safety of clinical administration effectiveness greatly.But existing Chinese medicine hemorrhage extracting method is very complicated, and the effective ingredient in the Herba Cirsii does not reach refining, and purification degree is not high, affects the treatment and the quality of the pharmaceutical preparations, and bleeding stopping period is long, and haemostatic effect is not clearly, and cost is than higher.
Three, summary of the invention
The present invention extracts haemostatic medicament method complexity in order to solve from the plant Herba Cirsii, purity is low, and the onset time of stopping blooding proposes a kind of new technical scheme slowly.
The present invention realizes by following scheme: a kind of method of from the Herba Cirsii plant, extracting haemostatic medicament, and its method step is as follows:
(1) decocting extracts: get the Herba Cirsii medical material, add 6-20 times of water boiling and extraction of medical material weight 1-3 time, each 1-3 hour, filter; Filtrate for later use;
(2) concentrating under reduced pressure: it is 1.05-1.15 that filtrate decompression is concentrated into relative density, leaves standstill 6-48 hour, filters;
(3) extract haemostatic medicament: above-mentioned filtrate adds concentrated hydrochloric acid and transfers to PH 1-5, adds ethyl acetate extraction 2-6 time, and the total consumption of ethyl acetate is 8-20 a times of medicine liquid volume, the reclaim under reduced pressure ethyl acetate;
(4) purification process: add water and make its dissolving, to liquor strength be 1-8g crude drug/ml, last D101, HPD-100, HPD-300, LSA-30 or LSA-33 macroporous adsorptive resins, behind the water elution of a water 2-6 column volume, reuse 10-30% ethanol elution, collecting eluent to total effluent volume is the 2-8 column volume, reclaim ethanol, and add water to every 1ml medicinal liquid and contain medical material 2-10g, in the bottle of packing into, lyophilizing, seal package.
The advantage that the present invention had is: the methods such as abstraction technique, macroporous absorption technology, freeze drying technology of using are carried out separation and purification to the plant Herba Cirsii extract composition that effectively stops blooding, the scientific and technological content and the quality of the pharmaceutical preparations of Herba Cirsii class formulation products have been improved greatly, making the freeze-dried powder dosage form is advanced modernized form of Chinese drug, intravenous administration is rapid-action, effect is strong, " first pass effect " of no liver is particularly suitable for internal medicine, gynecological bleeding class treatment of diseases.Extracting method of the present invention is simple, preparation technology advanced person, and the product purity height, clinical efficacy is reliable, and haemostatic effect is very obvious.
Four, the specific embodiment
Raw material: Herba Cirsii 1Kg;
From the method for raw material Herba Cirsii extraction haemostatic medicament, its method step is:
(1) decocting extracts: get Herba Cirsii medical material 1Kg, adding 10 times of water of medical material weight is that 10Kg decocts extraction 2 hours, filters; Medicinal residues added the 10Kg water boiling and extraction 1 hour again, merged secondary raffinate, and are standby;
(2) concentrating under reduced pressure: it is 1.06 that standby merge extractive liquid, is evaporated to relative density, leaves standstill 12 hours, filters;
(3) extract haemostatic medicament: above-mentioned filtrate adds concentrated hydrochloric acid and transfers to PH2-3, adds ethyl acetate extraction 4 times, and the total consumption of ethyl acetate is 10 times of medicine liquid volume, the reclaim under reduced pressure ethyl acetate;
(4) purification process: add water and make its dissolving, to liquor strength be 4g crude drug/ml, last macroporous adsorptive resins, behind the water elution of 2 column volumes of water, reuse 20% ethanol elution, collecting eluent to total effluent volume is 6 column volumes, reclaim ethanol, and add water to every 1ml medicinal liquid and contain medical material 5g, in the bottle of packing into, lyophilizing, seal package.
The hemorrhage pharmacodynamic experiment result that this method is produced is as follows:
Group dosage (g/Kg) number of animals bleeding time (s)
Matched group 12 203.6 ± 95.5
030402 40 10 112.2±103.9
030402 10 11 130.5±108.4
Etamsylate 025 10 127.6 ± 121.8
Prove that by experiment the present invention is applicable to wound hemorrhage, digestive tract hemorrhage to the function of spitting blood, having blood in stool, hematuria, hemoptysis, epistaxis and gynecological bleeding metrostaxis, dysfunctional uterine hemorrhage having quick-acting haemostatic powder, obviously reduces by the animal experiment proof bleeding time.
Claims (4)
- A kind of method of from the Herba Cirsii plant, extracting haemostatic medicament, it is characterized in that: method step is as follows:(1) decocting extracts: get the Herba Cirsii medical material, add 6-20 times of water boiling and extraction of medical material weight 1-3 time, each 1-3 hour, filter; Filtrate for later use;
- (2) concentrating under reduced pressure: it is 1.05-1.15 that filtrate decompression is concentrated into relative density, leaves standstill 6-48 hour, filters;
- (3) extract haemostatic medicament: above-mentioned filtrate adds concentrated hydrochloric acid and transfers to PH 1-5, adds ethyl acetate extraction 2-6 time, and the total consumption of ethyl acetate is 8-20 a times of medicine liquid volume, the reclaim under reduced pressure ethyl acetate;
- (4) purification process: add water and make its dissolving, to liquor strength be 1-8g crude drug/ml, last macroporous adsorptive resins, behind the water elution of a water 2-6 column volume, reuse 10-30% ethanol elution, collecting eluent to total effluent volume is the 2-8 column volume, reclaim ethanol, and add water to every 1ml medicinal liquid and contain medical material 2-10g, in the bottle of packing into, lyophilizing, seal package.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031345123A CN1318046C (en) | 2003-08-22 | 2003-08-22 | Extraction of styptic from cephalanoplos segetum |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031345123A CN1318046C (en) | 2003-08-22 | 2003-08-22 | Extraction of styptic from cephalanoplos segetum |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1582976A true CN1582976A (en) | 2005-02-23 |
| CN1318046C CN1318046C (en) | 2007-05-30 |
Family
ID=34597151
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB031345123A Expired - Fee Related CN1318046C (en) | 2003-08-22 | 2003-08-22 | Extraction of styptic from cephalanoplos segetum |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1318046C (en) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1059566C (en) * | 1995-01-28 | 2000-12-20 | 陕西金方药业有限公司 | Method for preparing hemostatic and its preparation |
-
2003
- 2003-08-22 CN CNB031345123A patent/CN1318046C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1318046C (en) | 2007-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2520305B1 (en) | Pharmaceutical composition including sunflower extract, preparative method and use thereof | |
| JPS60214741A (en) | Hypoglycemic agent | |
| US8945633B2 (en) | Pharmaceutical composition for preventing and treating inflammatory diseases containing an ethyl acetate fraction of dried extract of Trachelospermi caulis as an active ingredient, and method for producing the fraction | |
| US7799353B2 (en) | Pharmaceutical mixture for hepatitis treatment and its preparation method | |
| WO2022121986A1 (en) | Novel medicament for preventing and treating neurodegenerative diseases | |
| CN101843627B (en) | Application of dihydrophenanthrene glycoside compound in preparing medicines for preventing and curing cardiovascular and cerebrovascular diseases | |
| CN1616381A (en) | Process for preparing Erigeron breviscapus active component | |
| CN1768772A (en) | Compound formulation of breviscapine for treating cardiovascular and cerebrovascular diseases. its preparing process and application | |
| CN1112198C (en) | Thrombolytic medicine and its preparation and use | |
| CN115429752B (en) | Red sage root injection and its preparation method and application | |
| WO2022135329A1 (en) | Pharmaceutical composition containing erigerontis herba, ginseng radix et rhizoma, ophiopogonis radix and schisandrae chinensis fructus | |
| CN1318046C (en) | Extraction of styptic from cephalanoplos segetum | |
| CN105796625A (en) | Pharmaceutical composition containing red yeast rice and safflower and preparation thereof | |
| CN101240014B (en) | Lipopeptid composition with physiological activity and its preparation method and application | |
| KR20050041802A (en) | Polysaccharides of plants belonging to panax having effect on treatment and prevention of obesity | |
| CN101301304A (en) | Chinese medicinal composition for treating ischemic stroke and preparation thereof | |
| WO2009135433A1 (en) | Use of total salvianolic acid, panax notoginsenosides and combination thereof in treating septicemia | |
| CN100484517C (en) | A lyophilized powder for injection containing Notoginseng radix total saponin with good appearance and shatter resistance, and its preparation method | |
| CN110638854A (en) | Medicine or health food for preventing and/or treating Alzheimer's disease by thymus gland pathway | |
| CN1178890C (en) | Method for extracting hypericin from Hypericum perforatum and medicine made up using hypericin as main composition | |
| CN114681563B (en) | Pharmaceutical composition containing erigeron breviscapus, ginseng, ophiopogon root and schisandra chinensis | |
| CN1053817C (en) | Acanthopanax root injection freeze-dried powder injection and producing technology for acanthopanax root extract | |
| CN1692916A (en) | Pharmaceutical prepn. of compound mannite, and its prepn. method | |
| CN113712952A (en) | Preparation of tanshinol ethyl ester, pharmaceutical composition containing tanshinol ethyl ester and application of pharmaceutical composition in preparation of medicines for treating cerebral arterial thrombosis | |
| CN117860806A (en) | Pharmaceutical composition for dredging collaterals and protecting heart, preparation method thereof and pharmaceutical composition for dredging collaterals and protecting heart |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070530 Termination date: 20120822 |